Induction immunosuppression for lung transplantation with OKT3

Area of Science:

• Immunology
• Transplantation Medicine
• Pulmonology

Background:

• OKT3 (muromonab-CD3), an anti-CD3 monoclonal antibody, has been underutilized in lung transplantation due to safety concerns.
• These concerns include increased infectious risk and cardiopulmonary instability post-administration.

Purpose of the Study:

• To evaluate the safety and efficacy of OKT3 as induction immunosuppressive therapy in lung transplant recipients.
• To assess the impact of OKT3 on acute rejection and long-term outcomes like obliterative bronchiolitis.

Main Methods:

• A cohort of 52 lung transplant patients received OKT3 (5 mg/d IV for 10 days) with azathioprine and cyclosporine.
• Prophylactic ganciclovir and antifungal therapy were administered. Patients were monitored via transbronchial biopsy and pulmonary function tests.
• Cytomegalovirus infection was diagnosed by biopsy or antigenemia.

Main Results:

• The 30-day mortality was 4%, and in-hospital mortality was 8%. Acute graft failure occurred in 6 patients.
• No significant alterations in cardiopulmonary parameters were observed post-OKT3. Infections included Gram-negative (12 patients), Aspergillus (7), and CMV (8).
• Acute rejection was not observed during OKT3 administration. Long-term survival at 36 months was 74%+/-7%, with 69%+/-9% freedom from obliterative bronchiolitis.

Conclusions:

• OKT3 is a safe and effective induction immunosuppressive agent for lung transplantation.
• Its use is associated with limited acute rejection and may reduce the incidence of obliterative bronchiolitis.
• The study demonstrates a manageable safety profile with significant clinical benefits in lung transplant recipients.